CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗 CD19 CAR-T 细胞治疗后突变型 TP53 相关克隆性造血致致命性进展
英文原题：Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.
查看英文原题
Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们报告一例64岁男性患者，诊断为弥漫大B细胞淋巴瘤，在接受标准治疗后两次复发。由于持续性血细胞减少，进行了二代测序分析，发现一个小的TP53突变克隆。作为三线治疗，患者接受了CAR-T 细胞治疗，获得了完全缓解。然而，该治疗也导致了TP53突变克隆的扩增，以及伴有复杂异常核型的治疗相关骨髓增生异常。该病例可能作为接受CAR-T 细胞治疗患者中克隆性造血进展的典型示例，尤其是在存在TP53突变克隆的背景下。
展开英文摘要原文
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53 -mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission.
However, this treatment also led to the expansion of the TP53 -mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a TP53 -mutated clone.
论文信息
- 作者
- Eder LN、Martinovic D、Mazzeo P、Ganster C、Hasenkamp J、Thomson J、Trummer A、Haase D
- 单位
- Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 Göttingen, Germany.Germany
- 文献类型
- 病例报告
- 期刊
- Current oncology (Toronto, Ont.)2023 Jan 13
- 原文标识
- PubMed 36661736 · DOI 10.3390/curroncol30010087
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →